GDRX (GoodRx Holdings) Research & Development: $120.1 Mil (TTM As of Mar. 2026)


GDRX GoodRx Holdings Inc GDRX
60 GF Score
Price $2.70
GF Value $5.66
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is GoodRx Holdings Research & Development?

GoodRx Holdings GDRX -2.18% 60 Research & Development is $120.1 Mil as of Mar. 2026. GuruFocus rates GDRX with a GF Score™ of 60/100 and a GF Value™ of $5.66 (Possible Value Trap). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. GoodRx Holdings's Research & Development for the three months ended in Mar. 2026 was $30.2 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $120.1 Mil.

GoodRx Holdings  (NAS:GDRX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

GoodRx Holdings Research & Development Related Terms

GoodRx Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for GoodRx Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GoodRx Holdings Research & Development Chart

GoodRx Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 125.86 143.14 135.84 123.75 121.03

GoodRx Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.14 29.93 31.01 28.94 30.18
GDRX
60GF Score
GoodRx Holdings Inc GDRX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GoodRx Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $120.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $120.1 Mil mean?
GoodRx Holdings (GDRX) has a Research & Development of $120.1 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on GoodRx Holdings and its competitors.
Is GoodRx Holdings' Research & Development too high?
GoodRx Holdings' current Research & Development is $120.1 Mil. Overall, GoodRx Holdings has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does GoodRx Holdings' Research & Development compare to OMDA and CERT?
GoodRx Holdings' Research & Development of $120.1 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on GoodRx Holdings and its competitors. GoodRx Holdings's current Research & Development is $120.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GoodRx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GoodRx Holdings (GDRX) is currently considered Possible Value Trap. The stock's GF Value™ is $5.66, compared to a current price of $2.70 — trading 52.3% below its estimated fair value. The current Research & Development is $120.1 Mil. GoodRx Holdings' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For GoodRx Holdings (GDRX), the current Research & Development is $120.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GoodRx Holdings (GDRX) Overvalued in 2026?

Based on GuruFocus' analysis, GoodRx Holdings stock appears to be undervalued. The current stock price of $2.70 is trading 52.3% below its estimated GF Value™ of $5.66. GuruFocus considers GoodRx Holdings to be Possible Value Trap.

Key valuation signals for GDRX:

  • Research & Development: $120.1 Mil
  • GF Value™: $5.66 vs. price of $2.70 (52.3% below fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the GDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GoodRx Holdings Business Description

Other Exchanges 8GH:Germany
Address 2701 Olympic Boulevard, Santa Monica, CA, USA, 90404
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
60GF Score

Get the complete analysis for GDRX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.70
Price
$5.66
GF Value